Ipilimumab vs Tirzepatide
Ipilimumab vs Tirzepatide: Overview
This comparison examines the pharmacological differences between Ipilimumab and Tirzepatide.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Tirzepatide: Dual GIP and GLP-1 receptor agonist.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Tirzepatide β 5 days.
Chemical Properties
Type: Ipilimumab β Antibody; Tirzepatide β Protein.